Afficher la fiche abrégée
dc.contributor.author | World Health Assembly, 47 | |
dc.coverage.spatial | Geneva | EN |
dc.date.accessioned | 2015-06-27T12:53:01Z | |
dc.date.available | 2015-06-27T12:53:01Z | |
dc.date.issued | 1994 | |
dc.identifier.govdoc | WHA47.16 | |
dc.identifier.uri | https://iris.who.int/handle/10665/177384 | |
dc.description | (Agenda item 19) | EN |
dc.language.iso | en | EN |
dc.publisher | World Health Organization | EN |
dc.subject | Resolutions and decisions | EN |
dc.subject | Pharmaceutical products | EN |
dc.subject.mesh | Pharmaceutical Preparations | EN |
dc.subject.mesh | Drug Industry | EN |
dc.subject.mesh | Marketing | EN |
dc.subject.mesh | Ethics, Pharmacy | EN |
dc.subject.mesh | Health Planning | EN |
dc.subject.mesh | Health Policy | EN |
dc.subject.mesh | World Health Organization | EN |
dc.title | WHO ethical criteria for medicinal drug promotion | EN |
dc.type | Governing body documents | EN |
dc.subject.meshqualifier | ethics | EN |
Fichier(s) constituant ce document
- Nom:
- WHA47_R16_eng.pdf
- Taille:
- 1.411Mo
- Format:
- PDF
Ce document figure dans la(les) collection(s) suivante(s)
Afficher la fiche abrégée